Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
USA

FDA approves drug to treat menopausal hot flashes

The Food and Drug Administration announced Friday that it has approved a new class of drugs to treat the moderate to severe hot flashes that cause it. menopauseThis could provide reassurance to millions of women who do not want to undergo hormone therapy to treat their symptoms.

Pharmaceutical company Astellas Pharma said the pill (Fezolinetant, brand name “Veozah”) could be available in pharmacies within three weeks. Take the medicine once a day.

that works to block A chemical in the brain that affects how body temperature is regulated.The company touts the drug as a problem-solving milestone root cause What doctors call the vasomotor symptoms of menopause.

80% of women face hot flashes like them Age to 40s and 50s.Some people can manage it in an easy way lifestyle changeavoiding alcohol, and wearing layers.

However, hot flashes can be debilitating in some people, forcing women to experience rapid and unpredictable symptoms. Take a break from work and change their lives. Up to 46% of women have experienced moderate or severe hot flashes for many years, one study found.

Dr. Janet Maynard of the FDA said, “Menopausal hot flashes can be a significant physical burden for women and affect their quality of life.” statement announced approval.

Package of Veozah tablets
The FDA has approved the drug Veozah to treat hot flashes caused by menopause.

Astellas Pharma US, Inc.


Fezolinetant is not the first drug approved The FDA uses it to treat menopause, but it’s not what it used to be.

For decades, hormone replacement therapy has been used as a treatment Recommended Professional treatment for severe symptoms of menopause.

However, the use of these treatments has declined sharply following the results of government-funded research. Commitment to Women’s Health In 2002, he suggested that taking a combination of estrogen and progestin could increase the risk of alarming conditions such as breast cancer and heart disease.

This has led to experts doing their own customizations. guidanceBut for many women who suffer from symptoms, evidence shows that the benefits still outweigh the risks, they say.

The antidepressant paroxetine is the main non-hormonal therapy alternative available to women.However, the approval controversial And experts consider it less effective.

Although no true, head-to-head studies comparing fesolinetant with menopausal hormone therapy (MHT) have been published, previous research on this drug suggests that fesolinetant may be a promising alternative.

“In the short term, the safety and tolerability of fesolinetant and MHT appear comparable. However, long-term use of MHT is associated with significant increased risks,” reports the Clinical Economics Review Institute. writing in writing. last year.

Other options may soon become available in this market. Astellas Pharma Inc. Estimate It could reach $1 billion in 2016.Pharmaceutical company Bayer advances to finals Phase 3 trial The drug, called Erinzanetant, takes a similar approach.

“The introduction of new molecules to treat moderate-to-severe menopausal hot flashes will provide additional safe and effective treatment options for women,” said Dr. Maynard.

Summarize this content to 100 words

The Food and Drug Administration announced Friday that it has approved a new class of drugs to treat the moderate to severe hot flashes that cause it. menopauseThis could provide reassurance to millions of women who do not want to undergo hormone therapy to treat their symptoms.Pharmaceutical company Astellas Pharma said the pill (Fezolinetant, brand name “Veozah”) could be available in pharmacies within three weeks. Take the medicine once a day. that works to block A chemical in the brain that affects how body temperature is regulated.The company touts the drug as a problem-solving milestone root cause What doctors call the vasomotor symptoms of menopause.

80% of women face hot flashes like them Age to 40s and 50s.Some people can manage it in an easy way lifestyle changeavoiding alcohol, and wearing layers.However, hot flashes can be debilitating in some people, forcing women to experience rapid and unpredictable symptoms. Take a break from work and change their lives. Up to 46% of women have experienced moderate or severe hot flashes for many years, one study found.

Dr. Janet Maynard of the FDA said, “Menopausal hot flashes can be a significant physical burden for women and affect their quality of life.” statement announced approval.

The FDA has approved the drug Veozah to treat hot flashes caused by menopause.

Astellas Pharma US, Inc.

Fezolinetant is not the first drug approved The FDA uses it to treat menopause, but it’s not what it used to be. For decades, hormone replacement therapy has been used as a treatment Recommended Professional treatment for severe symptoms of menopause. However, the use of these treatments has declined sharply following the results of government-funded research. Commitment to Women’s Health In 2002, he suggested that taking a combination of estrogen and progestin could increase the risk of alarming conditions such as breast cancer and heart disease.

This has led to experts doing their own customizations. guidanceBut for many women who suffer from symptoms, evidence shows that the benefits still outweigh the risks, they say.The antidepressant paroxetine is the main non-hormonal therapy alternative available to women.However, the approval controversial And experts consider it less effective.Although no true, head-to-head studies comparing fesolinetant with menopausal hormone therapy (MHT) have been published, previous research on this drug suggests that fesolinetant may be a promising alternative.“In the short term, the safety and tolerability of fesolinetant and MHT appear comparable. However, long-term use of MHT is associated with significant increased risks,” reports the Clinical Economics Review Institute. writing in writing. last year.Other options may soon become available in this market. Astellas Pharma Inc. Estimate It could reach $1 billion in 2016.Pharmaceutical company Bayer advances to finals Phase 3 trial The drug, called Erinzanetant, takes a similar approach.”The introduction of new molecules to treat moderate-to-severe menopausal hot flashes will provide additional safe and effective treatment options for women,” said Dr. Maynard.

Alexander Ting

CBS News reporter covering public health and pandemics.

https://www.cbsnews.com/news/fda-approves-veozah-to-treat-hot-flashes-astellas-pharma/ FDA approves drug to treat menopausal hot flashes

Back to top button